An RGD-Modified MRI-Visible Polymeric Vector for Targeted siRNA Delivery to Hepatocellular Carcinoma in Nude Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wu, Chun ^a,b   Gong, Faming ^b   Pang, Pengfei ^a,b   Shen, Min ^a,b   Zhu, Kangshun ^a,b   Cheng, Du ^b   Liu, Zhihao ^a   Shan, Hong ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CASPASE 3; MESSENGER RNA; POLYETHYLENEIMINE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR VOLUME; ZETA POTENTIAL;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

MUS MUSCULUS;

EID: 84878760307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066416     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2001) Estimating the world cancer burden:Globocan 2000. Int J Cancer 94: 153-156.
2. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
4. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature.391: 806-811.
5. Wu Y, Wang W, Chen Y, Huang K, Shuai X, et al. (2010) The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 5: 129-136.
6. Ambrosini G, Adida C, Altieri DC, (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
7. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, et al. (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080-1085.
8. Altieri DC, (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482.
9. Peer D, Lieberman J, (2011) Special delivery: targeted therapy with small RNAs. Gene Ther 18: 1127-1133.
10. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J, (2007) Interfering with disease:a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453.
11. El-Aneed A, (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94: 1-14.
12. Chen G, Chen W, Wu Z, Yuan R, Li H, et al. (2009) MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials 30: 1962-1970.
13. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, et al. (2009) Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138: 148-159.
14. Shen M, Gong F, Pang P, Zhu K, Meng X, et al. (2012) An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine 7: 3319-3332.
15. Kumar CC, (2003) Intergrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131.
16. Weidner N, Semple JP, Welch WR, Folkman J, (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
17. Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, et al. (2010) Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol 17: 3379-3385.
18. Fuke H, Shiraki K, Suqimoto K, Tanaka J, Beppu T, et al. (2007) Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 363: 738-744.
19. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG, (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Controlled Release 12: 107-116.
20. Cai LL, Liu P, Li X, Huang X, Ye YQ, et al. (2011) RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomedicine 6: 3499-3508.
21. Thomas M, Klibanov AM, (2003) Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol 62: 27-34.
22. Green JJ, Chiu E, Leshchiner ES, Shi J, Langer R, et al. (2007) Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett 7: 874-879.
23. Bellin MF, Zaim S, Auberton E, Sarfati G, Duron JJ, et al. (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193: 657-663.
24. Wang YX, Hussain SM, Krestin GP, (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11: 2319-2331.